Contributor: Jenny Herr, Health Leaders InterStudy Employers are becoming more aware of specialty pharma costs, according to a recent survey from the Midwest Business Group
FDA approval yesterday of heart failure drug sacubitril/valsartan (Entresto), previously known as LCZ696, and the pending approval of two PCSK9 inhibitors this summer has reinvigorated
LINK TO REPORT: Innovation drives progress,” suggests the US Food and Drug Administration (FDA) in its report on the 41 new molecular entities and new
Published: March 16, 2015, Employee Benefit News Authors: Cheryl Larson, Vice President, Midwest Business Group on Health and Randy Vogenberg, Principal, Integrated Healthcare Institute Earlier
Mailing Address:
211 S. Clark #2749, Chicago, IL 60604
Phone: 312-372-9090
